Jacobio Pharma employs advanced technologies in its drug discovery and development processes, particularly focusing on targeting previously undruggable proteins. The company utilizes its proprietary Induced Allosteric Drug Discovery Platform (IADDP), which integrates various experimental and computational techniques to identify allosteric binding sites and mechanisms. This platform is designed to accelerate the discovery of novel allosteric molecules, enabling Jacobio to create drugs that can effectively modulate the function of target proteins. By employing sophisticated methods such as gene editing, nuclear magnetic resonance (NMR), and molecular simulations, Jacobio aims to uncover the intricate relationships between protein conformation and function, ultimately leading to the development of innovative therapeutics.

In addition to the IADDP, Jacobio is actively engaged in research and development across multiple oncogenic signaling pathways, including RAS, P53, and MYC. The company’s pipeline features a range of targeted therapies, including KRAS inhibitors and SHP2 inhibitors, which are designed to address specific mutations and pathways associated with various cancers. Jacobio's commitment to combination therapies and synergistic strategies further enhances its potential to improve treatment outcomes for cancer patients. With a robust portfolio of ongoing projects and collaborations, Jacobio is positioned at the forefront of cancer drug development, leveraging its in-house capabilities to bring novel therapies to market.

China

Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform.

Jacobio

Company Details